• Je něco špatně v tomto záznamu ?

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

K. Musilova, J. Devan, K. Cerna, V. Seda, G. Pavlasova, S. Sharma, J. Oppelt, R. Pytlik, V. Prochazka, Z. Prouzova, M. Trbusek, L. Zlamalikova, K. Liskova, L. Kruzova, M. Jarosova, A. Mareckova, C. Kornauth, I. Simonitsch-Klupp, AI. Schiefer, O....

. 2018 ; 132 (22) : 2389-2400. [pub] 20180913

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035018

Grantová podpora
NV16-29622A MZ0 CEP - Centrální evidence projektů

Follicular lymphoma (FL) is a common indolent B-cell malignancy with a variable clinical course. An unfavorable event in its course is histological transformation to a high-grade lymphoma, typically diffuse large B-cell lymphoma. Recent studies show that genetic aberrations of MYC or its overexpression are associated with FL transformation (tFL). However, the precise molecular mechanisms underlying tFL are unclear. Here we performed the first profiling of expression of microRNAs (miRNAs) in paired samples of FL and tFL and identified 5 miRNAs as being differentially expressed. We focused on one of these miRNAs, namely miR-150, which was uniformly downmodulated in all examined tFLs (∼3.5-fold), and observed that high levels of MYC are responsible for repressing miR-150 in tFL by binding in its upstream region. This MYC-mediated repression of miR-150 in B cells is not dependent on LIN28A/B proteins, which influence the maturation of miR-150 precursor (pri-miR-150) in myeloid cells. We also demonstrated that low miR-150 levels in tFL lead to upregulation of its target, namely FOXP1 protein, which is a known positive regulator of cell survival, as well as B-cell receptor and NF-κB signaling in malignant B cells. We revealed that low levels of miR-150 and high levels of its target, FOXP1, are associated with shorter overall survival in FL and suggest that miR-150 could serve as a good biomarker measurable in formalin-fixed paraffin-embedded tissue. Overall, our study demonstrates the role of the MYC/miR-150/FOXP1 axis in malignant B cells as a determinant of FL aggressiveness and its high-grade transformation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035018
003      
CZ-PrNML
005      
20240416075650.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2018-06-855502 $2 doi
035    __
$a (PubMed)30213873
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Musilová, Kateřina $7 xx0244506 $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
245    10
$a miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels / $c K. Musilova, J. Devan, K. Cerna, V. Seda, G. Pavlasova, S. Sharma, J. Oppelt, R. Pytlik, V. Prochazka, Z. Prouzova, M. Trbusek, L. Zlamalikova, K. Liskova, L. Kruzova, M. Jarosova, A. Mareckova, C. Kornauth, I. Simonitsch-Klupp, AI. Schiefer, O. Merkel, H. Mocikova, P. Burda, K. Machova Polakova, L. Kren, J. Mayer, CS. Zent, M. Trneny, AG. Evans, A. Janikova, M. Mraz,
520    9_
$a Follicular lymphoma (FL) is a common indolent B-cell malignancy with a variable clinical course. An unfavorable event in its course is histological transformation to a high-grade lymphoma, typically diffuse large B-cell lymphoma. Recent studies show that genetic aberrations of MYC or its overexpression are associated with FL transformation (tFL). However, the precise molecular mechanisms underlying tFL are unclear. Here we performed the first profiling of expression of microRNAs (miRNAs) in paired samples of FL and tFL and identified 5 miRNAs as being differentially expressed. We focused on one of these miRNAs, namely miR-150, which was uniformly downmodulated in all examined tFLs (∼3.5-fold), and observed that high levels of MYC are responsible for repressing miR-150 in tFL by binding in its upstream region. This MYC-mediated repression of miR-150 in B cells is not dependent on LIN28A/B proteins, which influence the maturation of miR-150 precursor (pri-miR-150) in myeloid cells. We also demonstrated that low miR-150 levels in tFL lead to upregulation of its target, namely FOXP1 protein, which is a known positive regulator of cell survival, as well as B-cell receptor and NF-κB signaling in malignant B cells. We revealed that low levels of miR-150 and high levels of its target, FOXP1, are associated with shorter overall survival in FL and suggest that miR-150 could serve as a good biomarker measurable in formalin-fixed paraffin-embedded tissue. Overall, our study demonstrates the role of the MYC/miR-150/FOXP1 axis in malignant B cells as a determinant of FL aggressiveness and its high-grade transformation.
650    _2
$a nádorová transformace buněk $x genetika $x patologie $7 D002471
650    _2
$a down regulace $7 D015536
650    _2
$a forkhead transkripční faktory $x genetika $7 D051858
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a folikulární lymfom $x diagnóza $x genetika $x patologie $7 D008224
650    _2
$a difúzní velkobuněčný B-lymfom $x genetika $x patologie $7 D016403
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny c-myc $x genetika $7 D016271
650    _2
$a represorové proteiny $x genetika $7 D012097
650    _2
$a aktivace transkripce $7 D015533
650    _2
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Deván, Ján $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 xx0316056
700    1_
$a Cerna, Katerina $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Seda, Vaclav $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Pavlasova, Gabriela $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Sharma, Sonali $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Oppelt, Jan $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Pytlik, Robert $u First Department of Medicine - Department of Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Prochazka, Vit $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic.
700    1_
$a Prouzová, Zuzana, $d 1979- $7 xx0105473 $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic.
700    1_
$a Trbusek, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Zlamalikova, Lenka $u Department of Pathology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Liskova, Kvetoslava $u Department of Pathology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Kruzova, Lenka $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic.
700    1_
$a Jarosova, Marie $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic.
700    1_
$a Mareckova, Andrea $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Kornauth, Christoph $u Department of Clinical Pathology, Medical University Vienna, Vienna, Austria.
700    1_
$a Simonitsch-Klupp, Ingrid $u Department of Clinical Pathology, Medical University Vienna, Vienna, Austria.
700    1_
$a Schiefer, Ana-Iris $u Department of Clinical Pathology, Medical University Vienna, Vienna, Austria.
700    1_
$a Merkel, Olaf $u Department of Clinical Pathology, Medical University Vienna, Vienna, Austria.
700    1_
$a Mocikova, Heidi $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Burda, Pavel $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Pathological Physiology, First Medical Faculty, Charles University, Prague, Czech Republic; and.
700    1_
$a Machova Polakova, Katerina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Kren, Leos $u Department of Pathology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Zent, Clive S $u Departments of Pathology and Laboratory Medicine and Medicine, University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY.
700    1_
$a Trneny, Marek $u First Department of Medicine - Department of Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Evans, Andrew G $u Departments of Pathology and Laboratory Medicine and Medicine, University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY.
700    1_
$a Janikova, Andrea $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Mraz, Marek $u Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 132, č. 22 (2018), s. 2389-2400
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30213873 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20240416075647 $b ABA008
999    __
$a ok $b bmc $g 1451678 $s 1073568
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 132 $c 22 $d 2389-2400 $e 20180913 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a NV16-29622A $p MZ0
LZP    __
$a Pubmed-20191007
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace